Drugs / UNR844-Cl
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03809611 | Apr → Dec 2019 | presbyopia | Novartis Pharmaceuticals | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UNR844-Cl | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03809611 ↗ |
| Route | Topical | “1.5% Ophthalmic solution for topical ocular administration” NCT03809611 ↗ |